http://www.jnj.com/connect/healthcare-products/consumer/?flash=true

http://www.jnj.com/connect/healthcare-products/medical-technologies/

http://www.jnj.com/connect/healthcare-products/prescription/

http://www.investor.jnj.com/investor-relations.cfm

http://www.jnjbtw.com/

Johnson & Johnson - Index

Johnson & Johnson - report - Index

OUR PRODUCTS
CONSUMER
The Consumer companies of Johnson & Johnson produce
products for baby and kids care, skin care, oral care, wound
care and women’s health care, as well as nutritional and
over-the-counter pharmaceutical products. These products
are marketed principally to the general public and sold both
to wholesalers and directly to independent and chain retail
outlets throughout the world. Some familiar brand names are
JOHNSON’S® Baby line of products, BAND-AID® Brand Adhesive
Bandages, BENGAY® patches and cream, NEUTROGENA® skin
and hair care products, TYLENOL® and MOTRIN®.
MEDICAL DEVICES AND DIAGNOSTICS
Our medical device companies develop, market and sell more
medical devices than any other company in the world. This
business segment includes a broad range of products used by,
or under the direction, of health care professionals. Product
lines include suture and mechanical wound closure products,
surgical equipment and devices, wound management and
infection prevention products, interventional and diagnostic
cardiology products, diagnostic equipment and supplies,
joint replacements and disposable contact lenses. Some
familiar brand names are ACUVUE® Brand Contact Lenses
and ONETOUCH® blood glucose meters.
PHARMACEUTICAL
Prescription medications from our pharmaceutical and
biotechnology companies represent major strides in
medicine since World War II. We market products in the
following therapeutic areas: anti-fungal, anti-infective,
cardiovascular, contraceptive, dermatology, gastrointestinal,
hematology, immunology, neurology, oncology, pain
management, psychotropic (central nervous system),
urology and virology. Well known brands include
REMICADE®, LEVAQUIN®, and PROCRIT®.
DELIVERING SHAREHOLDER VALUE
FACTS
2007 NET TRADE SALES BY SEGMENT
TOTAL SALES $61.1 BILLION
Medical Devices
and Diagnostics
$21.7 billion
Pharmaceutical
$24.9 billion
Consumer
$14.5 billion*
Johnson & Johnson is
one of only five industrial
companies with a
Triple A credit rating.
PERCENT INCREASE FROM 2006
CONSUMER 48.3%*
MEDICAL DEVICES 7.2%
AND DIAGNOSTICS
PHARMACEUTICAL 6.9%
*reflects the acquisition of
Pfizer Consumer Healthcare
during 2007
Johnson & Johnson
was ranked 36th on the
2007 FORTUNE 500.
ENGAGING WITH STAKEHOLDERS
Johnson & Johnson has a wide range of communication
mechanisms that enable us to solicit, hear, analyze and incorporate
the opinions of the stakeholders defined in Our Credo.
Our engagement pathways include formal dialogue with
individual interest groups, partnerships with non-governmental
organizations, consumer panels and call centers, employee
surveys and active community engagement by our facilities.
We do not limit stakeholder engagement to formal
discussion around a table, although that is certainly a piece
of our engagement process. Stakeholder engagement at
Johnson & Johnson is multifaceted, intricate and constant.
In mid-2007, we expanded our engagement pathways
through the launch of a corporate blog. JNJ BTW (By The
Way) has created more opportunities to dialogue directly
with customers, employees and other stakeholders. Our
Media Relations staff makes blog entries a couple times per
week and topics range from comments on industry news to
discussion of our business strategies. A challenge of corporate
blogging is managing the balance between transparency, legal
considerations and protected business interests. Nonetheless,
our blog has been very successful. We have been able to provide
the context, nuance and perspective that creates a more
complete picture of the Company and the ensuing dialogues
are thoughtful and rich, often informing internal business
decisions. Comments are allowed and encouraged, but also
moderated; guidelines for acceptable content are posted on
the blog. Our goal for 2008 is to bring more internal contributors
to the blog, thereby increasing the breadth of topics.
Examples of other recent stakeholder interactions
included a meeting with the Dogwood Alliance to discuss
how Johnson & Johnson approaches forest stewardship
matters, discussions with Innovest Strategic Advisors and
Oxfam International regarding Access to Medicines and
our biannual employee Credo survey.
2007 SALES BY REGION
United States
$32.4 billion
$4.7
billion
Europe
$15.7 billion
Asia-Pacific
and Africa
$8.3 billion
Western Hemisphere
(Excluding U.S.)
PERCENT OF TOTAL SALES
UNITED STATES 53%
EUROPE 25%
ASIA/PACIFIC AND AFRICA 14%
WESTERN HEMISPHERE
(excluding U.S.) 8%
Johnson & Johnson is one of only
four U.S. industrial companies with a
Triple A credit rating in both Standard
and Poor’s and Moody’s.
4 JOHNSON & JOHNSON 2007 SUSTAINABILITY REPORT